Endovalve
is a spinout of the University of Pennsylvania School of Medicine
that is developing a percutaneous mitral valve replacement
system to treat mitral regurgitation, an increasingly common
heart disease. Some 25,000 mitral valve replacements and about
13,000 mitral valve repairs are annually performed in the
United States alone, but only the severest cases are treated
today because of the risks of open-heart surgery. The Endovalve
system is designed to allow for a complete mitralvalve replacement
without open-heart surgery so that many more sufferers will
not have to defer treatment until the disease becomes critical
or a serious cardiac event takes place. Battelle Ventures
and its affiliate fund, Innovation Valley Partners, were the
sole investors in the company's series A financing. Battelle
Ventures General Partner Tracy Warren serves on the Board
of Directors.
The
Endovalve device is in the early stages of design development
and has not been approved
for clinical use nor has an Investigational Device Exemption
(IDE) been filed. No clinical studies have yet been planned
or initiated. (See deal announcement)
Company
Web Site
www.endovalve.com
|
